UNIVERSITY OF CALIFORNIA, DAVIS
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1905-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ucdavis.edu
Clinical Trials
759
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (627 trials with phase data)• Click on a phase to view related trials
ctDNA-Informed Management of Early-Stage Rectal Cancer
- Conditions
- Rectal AdenocarcinomaRectal CancerEarly-stage Rectal CancerLocally Advanced Rectal Adenocarcinoma
- Interventions
- Drug: Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 200
- Registration Number
- NCT07209215
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
- Conditions
- Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaRefractory Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Malignant Solid NeoplasmUnresectable Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 52
- Registration Number
- NCT07189195
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Effect of Semiconductor Embedded Wearable Sleeve on Treatment of Primary Dysmenorrhea Symptoms
- Conditions
- Primary DysmenorrheaPrimary Dysmenorrhea (PD)Menstrual CrampsWomen's Health
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 100
- Registration Number
- NCT07176780
Pregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes
- Conditions
- Gestational Diabetes Mellitus (GDM)Diabetes Type 2Breastfeeding ContinuationBreastfeeding Support
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 10
- Registration Number
- NCT07176793
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- Procedure: Laser interstitial thermal therapy
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 20
- Registration Number
- NCT07145112
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 152
- Next
News
UC Davis Scientists Develop Non-Hallucinogenic LSD Derivative That Shows Promise for Schizophrenia Treatment
Researchers at UC Davis created JRT, a novel compound derived from LSD by repositioning just two atoms in its molecular structure, potentially offering a breakthrough treatment for schizophrenia without hallucinogenic effects.
Promising Alzheimer's Vaccine Targeting Tau Protein Advances Toward Human Trials
University of New Mexico researchers have developed a vaccine that generates antibodies against pathological tau protein (pT181), showing efficacy in both mice and non-human primates with strong immune responses.
CRISPR-Cas9 Reduces VEGF Levels in Monkeys, Shows Retinal Toxicity at High Doses
CRISPR-Cas9 targeting VEGFA delivered via AAV vectors reduces VEGF levels in monkeys, potentially treating choroidal neovascularisation (CNV).